key: cord-0924632-hwd082os
authors: Goncalves, J.; Julianao, A. M.; Charepe, N.; Alenquer, M.; Athayde, D.; Ferreira, F.; Archer, M.; Amorim, M. J.; Serrano, F.; Soares, H.
title: Non-neutralizing secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon BNT162b2 vaccination
date: 2021-05-04
journal: nan
DOI: 10.1101/2021.05.03.21256416
sha: 3f34cad2d41172b037c6ba6e39afc4a21fdae430
doc_id: 924632
cord_uid: hwd082os

In view of data scarcity to guide decision-making in breastfeeding women, we evaluated how mRNA vaccines impact immune response of lactating health care workers (HCW) and the effector profile of breast milk transferred immune protection. We show that upon BNT162b2 vaccination, immune transfer via milk to suckling infants occurs through secretory IgA (SIgA) and T cells. Functionally, spike-SIgA was non-neutralizing and its titers were unaffected by vaccine boosting, indicating that spike-SIgA is produced in a T-cell independent manner by mammary gland. Even though their milk was devoid of neutralizing antibodies, we found that lactating women had higher frequencies of RBD-reactive circulating memory B cells and more RBD-IgG antibodies, when compared to controls. Nonetheless, blood neutralization titers in lactating and non-lactating HCW were similar. Further studies are required to determine transferred antibodies and spike-T cells complete functional profile and whether they can mediate protection in the suckling infant.

Center, Rua Câmara Pestana, 6 1150-082 Lisbon, 20

Portugal. helena.soares@nms.unl.pt 21 22 23

Highlights 24

• Milk and blood responses to BNT162b2 vaccine are initially isotype 25 discordant 26

• Immune transfer via milk to suckling infants occurs by spike-reactive SIgA 27

and T cells 28

• Spike-reactive SIgA in the breastmilk is non-neutralizing and T-cell 29 independent 30

• Lactating vs non-lactating HCW had distinct cellular responses, despite 31 similar NT50 32 33

Introduction 57 58

Initial COVID-19 clinical trials of mRNA vaccines excluded lactating women, 59 causing a dearth of data to guide vaccine decision-making by health authorities 60 1 . Even after vaccine emergency authorization, breastfeeding HCW have been 61 advised to discontinue breastfeeding upon receiving COVID-19 mRNA vaccine 2 . 62 This is especially worrisome since infants are the children's age group most 63 shown that antibody production between lactating and non-lactating women 107 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.03.21256416 doi: medRxiv preprint While, circulating neutralizing IgG to BNT162b2 vaccine are optimally detected 184 after boost 44 , it is currently unknown whether vaccine induced milk antibodies 185 will provide neutralizing protection to the sucking infant [16] [17] [18] . Contemporaneously 186 with IgG surge in the blood (Fig. 2 A, B ; orange) at a median of 10 days after 187 vaccine second dose, we detected anti-spike and anti-RBD IgG (14/14), but not 188

IgM (0/14), in the milk (Fig. 2 A However, circulating anti-RBD IgA levels were augmented after vaccine second 194 dose ( Fig. 2B; orange) . 195

Next, we wanted to know whether vaccine boost altered SIgA profile in the milk. We compared SIgA reactivity to trimeric spike and its RBD domain after the 202 vaccination regimen by ELISA and found that there were no differences between 203 vaccine the first and second vaccine doses (Fig. 2 F, G) . The fact that vaccine 204 boost has no effect in the milk levels of spike-and RBD-reactive SIgA, suggests 205 that SIgA production by the mammary mucosa in response to the vaccine is made 206 in a T cell-independent manner. 207 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) In all, our data suggest that milk vaccine induced SIgA is likely produced in a T 216 cell independent manner. Moreover, spike-and RBD-reactive SIgA transferred 217 by the breast milk is unlikely to provide protection to the suckling infant through 218 SARS-CoV-2 neutralization. 219 220

While human IgA secreting B cells are retained in the mammary gland, functional 223

IgG secreting B cells can be transferred to the suckling infant via milk 14,25,46 . We 224 sought to evaluate whether RBD-reactive B cells were present in the milk of 225 breastfeeding HCW after both the first and second vaccine doses. We were only 226 able to detect CD3 -CD19 + B cells in 5 out of 14 milk samples (Fig 3 A, B) . 227

Consistent with previous report 25 , milk B cells were overwhelming IgDillustrating 228 that they had undergone class-switch ( Fig 3A) . Due the limited number of B cells 229 detected we were not able to assess the presence of RBD-reactive milk B cells. 230

Mainly due to hormonal changes, lactating women display distinct immune 231 responses 37 . To fully evaluate the B cell immune response to BTN162b2 vaccine 232 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.03.21256416 doi: medRxiv preprint in this population, we determined the frequency of antibody secreting RBD-233 reactive plasmablasts and memory B cells (Fig 3 B, C) . A clear population of 234 RBD-binding IgD -B cell population could be detected at ~10 days post vaccine 235 first dose (Fig 3 B, C; prime), whose frequency (~1.7%) remained unaltered upon 236 vaccine boost (Fig 3 B, C; boost) . We then analyzed the frequency of RBD-237 reactive plasmablasts and memory B cells. Both RBD-reactive plasmablasts and 238 memory B cells were detectable after vaccine prime (Fig. 3 B, C) . Upon vaccine 239 boost, only plasmablasts appear to increase in frequency (Fig. 3 B, C) . Curiously, Although we were not able to detect RBD-reactive B cells, we found that lactating 250 HCW had higher frequencies of RBD-reactive circulating memory B cells and 251 higher RBD-IgG antibodies, when compared to controls. 252 253

Emerging evidence suggests the requirement of both antibody-mediated and T 256 cell-mediated immunity for effective protection against SARS-CoV-2 47,48 . 257 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 4, 2021.

Importantly, these mammary gland T cells are transferred through the milk to the 258 nursing infant and mediate immune protection 27, 49 . 259

To detect trimeric spike specific CD4 + T cells in the milk and in circulation, we 260 used an Activation Induced Marker (AIM) assay using OX40 and CD25 dual 261 expression to detect spike reactivity 50-52 . Out of 14 breastfeeding HCW, we could 262 only robustly detect CD4 + T cells in the milk of 5 donors. After vaccine second 263 dose, spike-reactive OX40 + CD25 + CD4 + T cells could be detected in 100% of milk 264 samples with detectable CD4 + T cells (Fig. 4 A, B) . Suggesting that in addition to 265 non-neutralizing antibodies, spike-reactive CD4 + T cells are transferred through 266 the breastmilk, upon mRNA vaccination. 267

All breastfeeding vaccinated HCW possessed spike reactive OX40 + CD25 + CD4 + 268 T cells (median, 0.71%; IQR, 0.38-1.07) in circulation right after vaccine prime, 269

and their frequency was not altered by subsequent boost (Fig 4 B, cells. There was no correlation between spike-reactive T cells and RBD-reactive 277 plasmablasts or memory B cells (Fig. 4D) . 278

All together these data show that in addition to non-neutralizing antibodies, milk 279 also transfers spike-reactive T cells. The fact that spike-reactive T cells are only 280 detectable in the milk after vaccine boost, reinforces the view that spike/RBD-281 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. vaccination. Moreover, we immunophenotyped the B and T cell responses to the 298 vaccine in the milk and blood of lactating women. All together, these findings 299 indicate that a possible immune protection conferred by breastmilk will occur in a 300 neutralization-independent T cell-dependent fashion. In addition, the higher 301 frequency in RBD-memory B cells in lactating women raise the possibility of 302 increased duration of vaccine conferred immune protection. 303

A dramatic plunge of COVID-19 cases starts as early as 12 days after BNT162b2 304 first vaccine dose 38,39 . We found that early vaccine immune response in the blood 305 and in the breastmilk was isotype discordant. Whereas, breastmilk contained 306 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. By combining size exclusion chromatography with customized spike-ELISA, we 320 concluded that vaccination does in fact originate spike-reactive SIgA, which is 321 secreted predominately as tetramers. We detected SIgA in 57% of milk samples. 322

Our detected milk SIgA prevalence is on the lower-end of the interval of milk IgA 323 prevalence (61.8% to >80%) detected by others 16-20 . This discrepancy can 324

probably be ascribed to different experimental procedures. While we detected 325

SIgA in milk samples that had been diluted 50-fold, these previous works either 326 used undiluted milk samples or diluted them at a maximum of 5-fold. 327

Upon administration of influenza vaccine to pregnant women, neutralizing 328 influenza-specific IgA are effectively transferred to breast milk 15 . Whether mRNA 329

vaccines similarly promote the transfer of neutralizing spike-specific IgA to 330 breastmilk has remained unexplored. Our data elucidate that upon vaccination of 331 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.03.21256416 doi: medRxiv preprint lactating women with BNT162b2, milk secreted spike-reactive SIgA is non-332

neutralizing. This is in great contrast with COVID-19 infection, where neutralizing 333

IgA occurs in the milk of infected lactating women 56 . This is likely due to the fact 334 that SARS-CoV-2 infection effectively primes airway and gut mucosa immunity, 335 while the vaccine is defective in providing mucosal immunity. In fact, mucosal IgA 336 secretion has been shown to play an important role in the early control of SARS-337

CoV-2 infection 57 and a recent paper has shown that SIgA dimers cloned from 338 COVID-19 patients display a 7-fold higher neutralization capacity when compared 339

to IgG 58 . Importantly, our results show that spike-reactive SIgA titers are not in the infant's tissues [30] [31] [32] [33] [34] [35] [36] . This is due to a combination of a biochemical reaction 354 between infant's saliva and breast milk that protects lymphocytes from acid injury 355 5-7 , a decrease in enzyme and acid content in the infant's digestive tract 61,62 , and 356 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021.

an increase in gut permeability 31 . Despite the strong experimental support that 357 mRNA vaccine induced CD4 + T cells might play an important role in mediating 358 protection 45,63,64 especially in suboptimal neutralizing antibodies settings 65 , this 359 is, to the best of our knowledge, the first report to detect spike-reactive T cells in 360 the breast milk of vaccinated mothers. It is possible that milk transferred spike-361 reactive T cells might mediate protective function by seeding in the infant's upper 362 respiratory tract and gut. We found that spike-reactive T cells accounted for 363 ~3.5% of milk CD4 + T cells. Even though this frequency might seem low, it is 364 worth to have in mind that a suckling infant ingest large volumes of milk daily, 365

which implies the ingestion of significant quantities of spike-reactive T cells. 366

Prolactin, the hormone that induces milk production also functions as a cytokine 367 that plays an important role in immune activation 37 . Since breastfeeding women 368 were excluded from initial vaccine trials, we sought to compare their response to 369

BNT162b2 vaccine. We detected higher RBD-reactive IgG and IgA titers in 370 lactating women, nonetheless their neutralization titers were undistinguishable 371 from controls. These results are consistent with previous findings 17, 18 . In addition, 372

we found that lactating women had higher frequencies of RBD-reactive memory 373 B cells but lower frequencies of plasmablasts in circulation. Suggesting that the 374 immune response to the vaccine in lactating women might be veered toward 375 longer lasting memory in detriment of short-lived antibody production. Further 376 studies will be needed to determine if these cellular differences are maintained in 377 medium term and whether they will impact long term protection. 378

Here we show that upon BNT162b2 vaccination immune transfer to the 379 breastmilk does not involve neutralizing antibodies. In fact, milk transferred T 380 cells together with non-neutralizing antibodies might play an important role in 381 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wilcoxon test when appropriate. For unpaired data, Man-Whitney test was used 453 when appropriate. Spearman correlation was used for correlative analysis. 454 ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, ns = not significant. 455 456 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.03.21256416 doi: medRxiv preprint Wilcoxon test when appropriate. For unpaired data, t test was used for parametric 479 data and Man-Whitney test was used for non-parametric data when appropriate. 480 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wilcoxon test when appropriate. For unpaired data, t test was used for parametric 501 data and Man-Whitney test was used for non-parametric data when appropriate. 502

Pearson correlation was used for correlative analysis. ***p<0.001, *p<0.05, ns = 503 not significant. 504 505 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Acknowledgements 529

We are very grateful to all the participants of the study. We 530 thank Cláudia Andrade at CEDOC Flow Cytometry platform for technical support. 531 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. 

The authors declare no competing interests. 552 553

Blood and breastmilk from 14 nursing mothers were collected between day 7 and 556 16 and between day 7 and 13 post-immunization with Pfizer BTN162b2 mRNA 557 vaccine (Table S1 ). Blood from controls was collected between day 10 and 16 558 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.03.21256416 doi: medRxiv preprint after vaccine second dose (Table S2) were defined as the last dilution before the absorbance dropped below OD450 of 603 0.15. This value was established using plasma from pre-pandemic samples 604 collected from subjects not exposed to SARS-CoV-2 42 . For samples that 605 exceeded an OD450 of 0.15 at last dilution (1:10,9350), end-point titter was 606 determined by interpolation 67 . As previously described 42 , in each assay we used 607 6 internal calibrators from 2 high-, 2 medium-and 2 low-antibody producers that 608 has been diagnosed for COVID-19 through RT-PCR of nasopharyngeal and/or 609 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.03.21256416 doi: medRxiv preprint oropharyngeal swabs. As negative controls, we used pre-pandemic plasma 610 samples collected prior to July 2019. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.03.21256416 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.03.21256416 doi: medRxiv preprint

Inclusion of Pregnant and Lactating Persons in 677 COVID-19 Vaccination Efforts

Breastfeed or be 679 vaccinatedâ€"an unreasonable default recommendation

Coronavirus disease-19 deaths among children 682 and adolescents in an area of Northeast, Brazil: why so many? Tropical Medicine & 683

Epidemiology of COVID-19 Among Children in China

Maternal Milk T Cells Drive 687 Development of Transgenerational Th1 Immunity in Offspring Thymus

Transfer of Maternal Immune Cells by Breastfeeding: Maternal 690

Present in Breast Milk Localize in the Peyer's Patches of 691 the Nursed Infant

Immunoglobulin-secreting cells of maternal origin can be detected 693 in B cell-deficient mice

Evidence for transmission of lymphocyte 695 responses to tuberculin by breast-feeding

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Maternal IgG immune complexes induce food allergen-specific 697 tolerance in offspring

Leukocyte Populations in Human Preterm and Term Breast Milk 699 Identified by Multicolour Flow Cytometry

Immunologic factors in 701 human milk during the first year of lactation

IgM and Lactoferrin Contents of Human Milk During Early Lactation and 705 the Effect of Processing and Storage

Induction of secretory immunity and memory at mucosal surfaces. 707 Vaccine

Laouar, A. Maternal Leukocytes and Infant Immune Programming during 709

IgA and neutralizing antibodies to influenza a virus in 711 human milk: a randomized trial of antenatal influenza immunization

SARS-CoV-2-Specific Antibodies in Breast Milk After

Vaccination of Breastfeeding Women

COVID-19 mRNA vaccines drive differential Fc-functional profiles in 716 pregnant, lactating, and non-pregnant women

COVID-19 vaccine response in pregnant and lactating women: a 719 cohort study

SARS-CoV-2 722 antibodies detected in human breast milk postvaccination

MAIT cells, TCR γδ+ cells and ILCs cells in human breast milk 727 and blood from HIV infected and uninfected women

Immune cell-mediated protection of the mammary 730 gland and the infant during breastfeeding

Human breast milk T lymphocytes display the phenotype and 732 functional characteristics of memory T cells

Breast milk-derived antigen-specific CD8+ T cells: an 735 extralymphoid effector memory cell population in humans

Human Milk-Derived B Cells: A Highly Activated Switched Memory 738

Cell Population Primed to Secrete Antibodies

CD4+ T cells spontaneously producing human immunodeficiency 740 virus type I in breast milk from women with or without antiretroviral drugs

Activated and memory T lymphocytes in human milk

Saliva electrophoretic protein profiles in infants: Changes with age 746 and impact of teeth eruption and diet transition

Breastmilk-Saliva Interactions Boost Innate Immunity by 749 Regulating the Oral Microbiome in Early Infancy

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

The identification of secreted carbonic anhydrase VI as a 751 constitutive glycoprotein of human and rat milk

Intestinal Barrier Maturation in Very Low Birthweight Infants: 754 Relationship to Feeding and Antibiotic Exposure

Breastmilk cell trafficking induces microchimerism-mediated 757 immune system maturation in the infant

Cross-Generational Reproductive Fitness Enforced by 760

Microchimeric Maternal Cells

Long-Term Stable Mixed Chimerism after Hematopoietic Stem 762

Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant? 763

Early T cell and binding antibody responses are associated 765 with Covid-19 RNA vaccine efficacy onset

Vaccine-induced immunity provides more robust heterotypic 768 immunity than natural infection to emerging SARS-CoV-2 variants of concern

Endocrine System and the Immune System: A Review of the Inflammatory Role of 772

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Early rate reductions 777 of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. The 778

IgA tetramerization improves target breadth but not peak potency of 780 functionality of anti-influenza virus broadly neutralizing antibody

Multielemental distribution patterns in premature human milk whey and pre-term 784 formula milk whey by size exclusion chromatography coupled to inductively coupled 785 plasma mass spectrometry with octopole reaction cell

Evaluating SARS-CoV-2 Seroconversion Following Relieve of 788 Confinement Measures

Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of 790 immune evasion affecting antibody but not ACE2 binding

Distinct antibody and memory B cell responses in SARS-CoV-2 793 naïve and recovered individuals following mRNA vaccination

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

CCL28 controls immunoglobulin (Ig)A plasma cell 798 accumulation in the lactating mammary gland and IgA antibody transfer to the 799 neonate

Trans-epithelial 805 immune cell transfer during suckling modulates delayed-type hypersensitivity in 806 recipients as a function of gender

Immunological memory to SARS-CoV-2 assessed for up to 8 808 months after infection

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in 810 Humans with COVID-19 Disease and Unexposed Individuals

Selective and cross-reactive SARS-CoV-2 T cell epitopes in 813 unexposed humans

SARS-COV-2 infection in children and newborns: a systematic 815 review

The multifaceted roles of breast milk antibodies

Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in 819 Human Milk

Characterization of SARS-CoV-2 RNA, Antibodies, and 821 Neutralizing Capacity in Milk Produced by Women with COVID-19

IgA dominates the early neutralizing antibody response to SARS-824

Enhanced SARS-CoV-2 neutralization by dimeric IgA

The continuing story of T-cell 828 independent antibodies

Population homogeneity for the antibody response to COVID-19

Comirnaty vaccine is only reached after the second dose. medrxiv.org (2021)

Observations on the gastric acidity during the first month of life

A Study of Gastric Acidity in Infants

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in 837

Acute COVID-19 and Associations with Age and Disease Severity

Early induction of functional SARS-CoV-2-specific T cells 840 associates with rapid viral clearance and mild disease in COVID-19 patients

Correlates of protection against SARS-CoV-2 in rhesus 843 macaques

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol 845 for a Serological Assay, Antigen Production, and Test Setup

Repeated cross-sectional sero-monitoring of SARS-CoV-2 in 848

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)